Overview
- Vertex agreed to buy Crinetics in an all‑cash $85‑per‑share deal announced July 6 that values the company at roughly $10 billion and was unanimously approved by both boards.
- The acquisition moves approved oral acromegaly drug Palsonify and late‑phase Phase 3 ACTH antagonist atumelnant into Vertex’s portfolio, with Palsonify posting about $10–11 million in its first full commercial quarter.
- Vertex plans to fund the deal with cash plus debt, including a reported bridge facility, and expects the acquired assets could exceed $5 billion in peak annual sales and be earnings accretive by 2029.
- Crinetics shares nearly doubled after the announcement and now trade close to the $85 offer, so further upside is capped unless a competing bidder appears before the expected Q3 2026 close.
- Investors have repriced small endocrine drugmakers since the deal, and patients may see faster commercialization of an oral acromegaly option as Vertex integrates Crinetics while the transaction awaits regulatory and shareholder approvals.